title: Lamotrigine in patients with bipolar disorder and cocaine dependence.
abstract: BACKGROUND
  Bipolar disorder is associated with the highest substance abuse rates of any psychiatric illness. Therefore, treatments that stabilize mood and decrease drug use or cravings are of great interest. Open-label lamotrigine was examined in 30 outpatients with DSM-IV bipolar disorder and cocaine dependence. Lamotrigine was either added to existing medication regimens or used as monotherapy.
  
  
  METHODS
  Lamotrigine was started at a dose of 25 mg/day (12.5 mg/day in those taking valproic acid) and titrated to a maximum dose of 300 mg/day. Subjects received a baseline evaluation including a structured clinical interview and weekly assessments for 12 weeks with the Hamilton Rating Scale for Depression (HAM-D), Young Mania Rating Scale (YMRS), Brief Psychiatric Rating Scale (BPRS), and Cocaine Craving Questionnaire (CCQ). At each appointment, a urine sample was obtained, and participants reported drug use during the previous week. The subjects consisted of 13 men and 17 women with cocaine dependence and bipolar I disorder (N = 22), bipolar II disorder (N = 7), or bipolar disorder not otherwise specified (N = 1), with a mean +/- SD age of 35.4 +/- 7.2 years. Data were analyzed using the last observation carried forward on all subjects who completed the baseline evaluation and at least 1 postbaseline assessment.
  
  
  RESULTS
  Significant improvement was observed in HAM-D, YMRS, and BPRS scores (p < or =.02). Cravings also significantly decreased as measured by the CCQ (p <.001). Dollar amount spent on drugs decreased nonsignificantly. Lamotrigine was well tolerated, with no subjects discontinuing due to side effects.
  
  
  CONCLUSIONS
  Lamotrigine treatment was well tolerated in this sample and associated with statistically significant improvement in mood and drug cravings but not drug use. The findings suggest that larger controlled trials of lamotrigine are needed in this population.
authors.affiliation: Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas 75390, USA. sherwood.brown@utsouthwestern.edu
authors.forename: E Sherwood
authors.initials: ES
authors.lastname: Brown
authors.forename: Vicki A
authors.initials: VA
authors.lastname: Nejtek
authors.forename: Dana C
authors.initials: DC
authors.lastname: Perantie
authors.forename: Paul J
authors.initials: PJ
authors.lastname: Orsulak
authors.forename: Leonardo
authors.initials: L
authors.lastname: Bobadilla
mesh_terms: D000328:Adult; D000927:Anticonvulsants / Q000627:therapeutic use*; D016739:Behavior, Addictive / Q000175:diagnosis / Q000188:drug therapy / Q000523:psychology; D001714:Bipolar Disorder / Q000175:diagnosis / Q000188:drug therapy*; D019970:Cocaine-Related Disorders / Q000175:diagnosis / Q000188:drug therapy* / Q000523:psychology; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D000077213:Lamotrigine; D008297:Male; D010865:Pilot Projects; D011569:Psychiatric Status Rating Scales; D011619:Psychotropic Drugs / Q000627:therapeutic use; D016896:Treatment Outcome; D014227:Triazines / Q000627:therapeutic use*
chemical_list: D000927:Anticonvulsants; D011619:Psychotropic Drugs; D014227:Triazines; D000077213:Lamotrigine